Pharmaceutical Executive Daily: FDA Approves Darzalex Faspro
Update: 2025-11-10
Description
In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Darzalex Faspro for adults with high-risk smoldering multiple myeloma, the industry’s growing interest in direct-to-patient wholesale models, and the FDA’s expansion of its National Priority Voucher program to accelerate review of critical therapies.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
